Close



Apr 15, 2024 09:47AM
Apr 15, 2024 08:30AM
Apr 11, 2024 05:17PM
Apr 8, 2024 02:15PM
Apr 8, 2024 02:15PM
Apr 8, 2024 09:51AM
Apr 8, 2024 08:30AM Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
Mar 19, 2024 04:01PM
Mar 19, 2024 04:01PM
Feb 27, 2024 04:05PM
Nov 29, 2023 08:00AM
Nov 11, 2023 09:00AM
Sep 7, 2023 08:00AM
Aug 11, 2023 07:01AM Longeveron (LGVN) Acquires 50%+ Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B
Aug 11, 2023 07:00AM
May 12, 2023 08:00AM
May 9, 2023 08:30AM
May 9, 2023 08:30AM
Feb 28, 2023 08:30AM
Feb 28, 2023 08:30AM
Jan 19, 2023 08:32AM Longeveron (LGVN) Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal
Jan 19, 2023 08:30AM
Jan 6, 2023 09:58AM
Jan 6, 2023 08:30AM
Nov 14, 2022 08:00AM
Aug 31, 2022 08:30AM
Aug 12, 2022 08:00AM
May 13, 2022 08:00AM Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 9, 2022 04:17PM
May 9, 2022 04:15PM
Apr 5, 2022 08:02AM
Apr 5, 2022 08:00AM
Mar 11, 2022 08:00AM
Jan 12, 2022 08:00AM
Jan 12, 2022 08:00AM Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging
Jan 4, 2022 08:00AM
Dec 6, 2021 08:06AM
Dec 6, 2021 08:00AM
Nov 30, 2021 03:20PM
Nov 30, 2021 03:20PM
Nov 18, 2021 09:25AM
Nov 18, 2021 08:05AM Longeveron (LGVN) Announces FDA Approves its Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition
Nov 18, 2021 08:00AM
Sep 21, 2021 08:00AM
Sep 13, 2021 09:19AM
Aug 13, 2021 07:02AM
Aug 13, 2021 07:00AM
Apr 15, 2021 08:36AM
Apr 15, 2021 08:30AM Longeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza Vaccination
Apr 13, 2021 09:15AM

251,135 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All